Our attorneys have filed a mass tort lawsuit on behalf of patients who took the blood thinner Xarelto (rivaroxaban) and suffered severe bleeding events. Pharmaceutical firms, like the makers of Xarelto, possess a duty to ensure that their drugs are reasonably secure for use - and failure to do so may possibly be grounds for compensation. Our lawyers are operating tough to acquire these hurt by the drug the compensation they are entitled to.
While bleeding can be a frequent complication connected with anticoagulants, it has been alleged that Xarelto is much more hazardous than classic blood thinners because no antidote exists to reverse its blood-thinning effects. This implies that, in the occasion of an emergency, individuals may be at threat for irreversible bleeding issues, including life-threatening internal and gastrointestinal hemorrhaging.
If you or even a loved a single suffered a severe bleeding event soon after taking Xarelto, you might have legal recourse. For far more details, get in touch with us these days to have your case reviewed, free of charge.
xarelto-compensation-photoThe plaintiffs in these lawsuits are searching for compensation from Bayer and Janssen for previous and future healthcare bills, lost wages, pain and suffering and, in instances of death, funeral expenditures. In addition, they are searching for punitive damages, which are normally awarded to punish the defendant and deter other companies from acting similarly.
Why Are Lawsuits
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is hazardous and defective. The plaintiffs claim that, unlike traditional anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Due to the fact of this, the lawsuits claim, doctors have no effective means of stopping Xarelto users from bleeding within the occasion of an emergency. Plaintiffs in the lawsuits allege critical and fatal injuries, such as cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug as a superior in the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a secure anticoagulant option.
Doctors and medical staff were not properly made aware of methods to stabilize and treat a Xarelto user within the event of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding event.
Xarelto is linked to serious bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing harmful clotting.
Visit this page for far more data on the alleged health risks of xarelto and joint pain
Multidistrict Litigation Trial Dates Set
The attorneys in the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.